Biogen Idec Inc. Earnings Conference Call (Q1 2008)  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other Apr 23 Calls Today's Calls

Call Details Biogen Idec Inc. Earnings Conference Call (Q1 2008) Wed, Apr 23, 2008, 8:30 am Eastern Listen to the archived event audio About Biogen Idec Inc. (NasdaqGS:BIIB) Biogen Idec, Inc. engages in the development, manufacture, and commercialization of novel therapies primarily in the areas of oncology, neurology, immunology, and cardiology in the United States and internationally. Its products include AVONEX for the treatment of relapsing forms of multiple sclerosis (MS); RITUXAN for the treatment of relapsed or refractory low-grade or follicular, CD20-positive, B-cell non-Hodgkin’s lymphomas, or B-cell NHLs; TYSABRI for the treatment of relapsing forms of MS; and FUMADERM, an immunomodulator for the treatment of severe psoriasis. The company’s other products under development include BG-12, a Phase III clinical trial product for the treatment of MS; Anti-CD80 MAb/galiximab, a Phase III clinical product for relapsed or refractory NHL; Anti-CD23 MAb/lumiliximab, a Phase II/III clinical product for the treatment of relapsed or refractory chronic lymphocytic leukemia; Humanized Anti-CD20 MAb/Ocrelizumab, a Phase III clinical product for the treatment of Rheumatoid Arthritis; and Lixivaptan, a Phase III clinical drug for the treatment of Acute Hyponatremia. In addition, its preclinical stage products include Volociximab, CNF2024, Natalizumab, RAF (BIIB024), CNF3647, Anti CRIPTO, Anti IGF-1R, Daclizumab, CDP-323, BIIB014, Neublastin, Baminercept-alfa, Anti-TWEAK, anti-CD40L Fab, ADENTRI, Aviptadil, and Long acting rFactor IX. Biogen Idec has collaboration agreements with PDL BioPharma, Inc.; Sunesis Pharmaceuticals, Inc.; Vernalis plc; Vetter Pharma-Fertigung GmbH & Co. KG; Elan Corporation plc; Alnylam Pharmaceuticals, Inc.; UCB SA; Neurimmune SubOne AG; Cardiokine Biopharma LLC; and Schering AG. The company was founded in 1985 and is based in Cambridge, Massachusetts. More Info: Quote | Chart | News | Profile | Reports | Research | Msgs | Insider | Financials | Analyst Ratings